Solenopsin, the alkaloidal component of the fire ant (Solenopsis invicta), is a naturally occurring inhibitor of phosphatidylinositol-3-kinase signaling and angiogenesis
Open Access
- 21 September 2006
- journal article
- Published by American Society of Hematology
- Vol. 109 (2), 560-565
- https://doi.org/10.1182/blood-2006-06-029934
Abstract
Phosphatidylinositol-3-kinase (PI3K), and its downstream effector Akt, or protein kinase Bα (PKBα), play a major regulatory role in control of apoptosis, proliferation, and angiogenesis. PI3K and Akt are amplified or overexpressed in a number of malignancies, including sarcomas, ovarian cancer, multiple myeloma, and melanoma. This pathway regulates production of the potent angiogenic factor vascular endothelial growth factor (VEGF), and protects tumor cells against both chemotherapy and reactive oxygen–induced apoptosis through phosphorylation of substrates such as apoptotic peptidase–activating factor-1 (APAF-1), forkhead proteins, and caspase 9. Given its diverse actions, compounds that suppress the PI3K/Akt pathway have potential pharmacologic utility as angiogenesis inhibitors and antineoplastic agents. Using the SVR angiogenesis assay, a screen of natural products, we isolated the alkaloid solenopsin, and found that it is a potent angiogenesis inhibitor. We also found that solenopsin inhibits the PI3K signaling pathway in cells upstream of PI3K, which may underlie its affects on angiogenesis. Consistent with inhibition of the activation of PI3K, solenopsin prevented the phosphorylation of Akt and the phosphorylation of its substrate forkhead box 01a (FOXO1a), a member of the forkhead family of transcription factors. Interestingly, solenopsin also inhibited Akt-1 activity in an ATP-competitive manner in vitro without affecting 27 of 28 other protein kinases tested.Keywords
This publication has 40 references indexed in Scilit:
- A phase II study of perifosine (D-21226) in patients with previously untreated metastatic or locally advanced soft tissue sarcoma: A National Cancer Institute of Canada Clinical Trials Group trialInvestigational New Drugs, 2006
- Spectrum of activity and molecular correlates of response to phosphatidylinositol ether lipid analogues, novel lipid-based inhibitors of AktMolecular Cancer Therapeutics, 2006
- The specificities of protein kinase inhibitors: an updateBiochemical Journal, 2003
- Specificity and mechanism of action of some commonly used protein kinase inhibitorsBiochemical Journal, 2000
- The antiangiogenic agents TNP-470 and 2-methoxyestradiol inhibit the growth of angiosarcoma in miceJournal of the American Academy of Dermatology, 1999
- Akt/PKB localisation and 3′ phosphoinositide generation at sites of epithelial cell–matrix and cell–cell interactionCurrent Biology, 1999
- Vascular Endothelial Growth Factor Regulates Endothelial Cell Survival through the Phosphatidylinositol 3′-Kinase/Akt Signal Transduction PathwayJournal of Biological Chemistry, 1998
- Polyoma Middle T Antigen Activates the Ser/Thr Kinase Akt in a PI3-Kinase-Dependent MannerBiochemical and Biophysical Research Communications, 1998
- Insulin-like Growth Factor 1 Inhibits Apoptosis Using the Phosphatidylinositol 3′-Kinase and Mitogen-activated Protein Kinase PathwaysPublished by Elsevier BV ,1997
- Stages of embryonic development of the zebrafishDevelopmental Dynamics, 1995